<DOC>
	<DOCNO>NCT01088412</DOCNO>
	<brief_summary>GeNeSIS open-label , multinational , multicenter , observational study evaluate safety effectiveness Humatrope treatment . GeNeSIS modular program include : - Core study : Evaluating safety effectiveness Humatrope observational set - Genetic Analysis Sub-study : Investigating genetic defect underlie growth hormone ( GH ) deficiency non-GH-deficient growth disorder - Growth Prediction Sub-study : Working validate refine specific model accurately predict growth response GH - SHOX Deficiency Sub-study : Elucidating clinical , endocrine radiological feature patient SHOX deficiency due loss , mutation SHOX gene ( include patient Turner syndrome ) - Neoplasia Sub-study : To characterize natural history neoplastic disease , especially relation recurrence/progression primary neoplasia development secondary neoplasia child history neoplasia</brief_summary>
	<brief_title>Observational Study Somatropin Treatment Children</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<criteria>All patient participate GeNeSIS must enrol core study . Patients write consent release information provide may enter core study meet follow inclusion guideline : Treatment Humatrope improvement growth . No treatment somatropin patient history neoplasia SHOXrelated disorder . Patients close epiphysis eligible GeNeSIS entry . However , patient may remain study epiphyseal closure occur study participation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>